What is the best treatment?

Journal of Viral Hepatitis

Volumn 11, Issue SUPPL. 1, 2004, Pages 23-27

  Dillon, J F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

HCV; Interferon; Ribavirin; Treatment

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ALOPECIA; ANXIETY DISORDER; BONE MARROW TOXICITY; CHRONIC LIVER DISEASE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; FLU LIKE SYNDROME; HEALTH CARE ACCESS; HEALTH CARE COST; HEPATITIS C; HUMAN; LIFESTYLE; LIVER BIOPSY; MORBIDITY; MORTALITY; NAUSEA; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; VIRUS TRANSMISSION; LIVER CIRRHOSIS; REVIEW;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERONS; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES; RIBAVIRIN;

EID: 4944250098     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00573.x     Document Type: Conference Paper

References (12)

1. Poynard T, Marcellin P, Lee S et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
2. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. results of a randomized trial. Lancet 2001; 358: 948-965.
4. Fried MW, Shiffman ML, Reddy RK et al. Peginterferon alfa-2a (40KD:) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively controlled multicenter study. N Engl J Med 2002; 347: 975-82.
5. Hadziyannis SJ, Cheinquer H, Morgan T et al. Peginter feron alfa-2A (40: KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III. randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose (Abstract). J Hepatol 2002; 36 (Suppl. 1): 3.
6. Rosenberg WM, Bennett-Lloyd B, Parkes J, Roderick P. Differences between antiviral therapy trials may be attributed to chance. Hepatology 2002; 36: 378A.
7. US Food and Drug Administration. FDA briefing document. (http://www.fda.gov/ohrms/dockets/ac/02/briefing/3909B1 - 02_FDA%20briefing%20package%20.doc). Rockville, MD, USA: FDA.
8. Siebert U, Sroczynski G, Rossol S et al. Cost effectiveness of peg interferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-432.
9. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with Peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.
10. National Institute for Clinical Excellence. Hepatitis C - alpha interferon and ribavarin (No. 14). London: NICE; 2000.
11. Booth JCL, O'Grady J, Neuberger J. On behalf of the Royal College of Physicians of London and the British Society of Gastroenterology. Clinical Guidelines on the Management of Hepatitis C. London: British Society of Gastroenterology; 2001.
12. National Institute for Clinical Excellence. Hepatitis C - pegylated interferons, ribavirin and alfa interferon (no. 75). London: NICE; 2000.